Radioimmunotherapy of colorectal cancer in small volume disease and in an adjuvant setting: preclinical evaluation in comparison to equitoxic chemotherapy and initial results of an ongoing phase-I/II clinical trial.

@article{Behr1999RadioimmunotherapyOC,
  title={Radioimmunotherapy of colorectal cancer in small volume disease and in an adjuvant setting: preclinical evaluation in comparison to equitoxic chemotherapy and initial results of an ongoing phase-I/II clinical trial.},
  author={T. M. Behr and Stavros G Memtsoudis and Vassilios I. Vougioukas and Torsten Liersch and Stefan Gratz and Friederike Schmidt and Thomas Lorf and Stefan Post and Bernhard Josef W{\"o}rmann and Wolfgang Hiddemann and Bastian Ringe and Wolfgang T Becker},
  journal={Anticancer research},
  year={1999},
  volume={19 4A},
  pages={
          2427-32
        }
}
The 5-year survival of colorectal cancer patients with distant metastases is below 30%, despite the development and use of a variety of chemotherapeutic regimens. Therefore, new therapeutic strategies are warranted. Whereas radioimmunotherapy (RIT) has shown disappointing results in bulky disease, it may be a promising therapeutic alternative in limited and small volume disease. The aim of this study was, therefore, to compare, in a preclinical study, the therapeutic efficacy of RIT in… CONTINUE READING